Articles related to MEDICAL MEETINGS AND EVENTS

Results from the RUBY trial of dostarlimab and the GY018/Keynote-068 of pembrolizumab were presented at the 2023 SGO Annual Meeting on Women’s Cancer in March and were simultaneously published in The New England Journal of Medicine. The studies examined the efficacy and safety of the medications in all individuals and those with mismatch repair deficient (dMMR) illness. Each trial examined a separate PD-1 inhibitor, pembrolizumab or dostarlimab, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer. In individuals with dMMR illness, both medications lowered the chance of disease progression or death by roughly 70%.

Significant progress has been made in the last 20 years in the identification of therapeutically relevant oncogenic drivers in NSCLC. These oncogenic drivers have been the focus of targeted medicines that have been created to offer enhanced tailored treatment for NSCLC. To improve the choice of patient-specific treatment, an oral presentation at the 2023 ONA Summit Live Virtual Meeting compared guideline-directed targeted therapies based on patient and tumor characteristics. It also described collaborative strategies for managing therapy-related adverse events for this patient population. Key molecular characteristics in advanced NSCLC were also discussed, along with their relationships to current and emerging targeted therapies.

From side effect to mechanism of action to patient acceptance to managing insurance hurdles, this collection of expert points from the February Endocrine Society meeting is a helpful synopsis of need-to-know items for PCPs.

The event will be held on Tuesday, April 11th, 2023 from 5:00pm – 9:00pm at The Hermitage Hotel in Nashville, TN, in the Grand Ballroom. Tennessee Oncology’s Stephen Schleicher, MD, and Larry Bilbrey will be your hosts for this one-night event, which will provide commentary on how cancer care has become more complicated over the last 15 years and how data is disrupting delivery today and in the future, from the private sector to tech companies.